Summit Therapeutics plc Summit Therapeutics To Participate In Panel Sessions At The World Antimicrobial Resistance Congress

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Summit Therapeutics to Participate in Panel Sessions at the World 
Antimicrobial Resistance Congress 
 
   Oxford, UK, and Cambridge, MA, US, 6 November 2019 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that management 
will participate in two panel sessions at the World Antimicrobial 
Resistance Congress, taking place 7-8 November 2019 in Washington, DC. 
 
   In the panel sessions, Dr David Roblin, Chief Operating Officer and 
President of R&D, Dr Richard Vickers, Chief Scientific Officer, and Dr 
David Powell, Head of Research, will highlight the potential benefits of 
developing new mechanistic classes of precision antibiotics, including 
potency against resistant and non-resistant bacteria with minimal 
disturbance to the gut microbiome. This supports the principles of 
antibiotic stewardship. 
 
   Details of the sessions: 
 
   Date: 7 November 2019 
 
   Time: 2:10pm EST 
 
   Session: Roundtable 3 Innovation & Stewardship -- Advancing narrow 
spectrum, new mechanism antibiotics as precision agents to by-pass 
resistance and to support antibiotic stewardship 
 
   Date: 8 November 2019 
 
   Time: 1:00pm EST 
 
   Session: C-Suite Keynote Panel: Balancing continued innovation in R&D 
while navigating funding, stewardship and the overall commercial 
landscape 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)     Tel:                  44 (0)1235 443 951 
Michelle Avery (US office)                                          +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                  Tel:                 +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                  Tel:                 +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer, Corporate 
 Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)  Tel:                 +44 (0)20 7332 2500 
Phil Walker / Dominic Wilson 
MSL Group (US)                             Tel:                     +1 781 684 6652 
                                                         mailto:summit@mslgroup.com 
Erin Anthoine                                                   summit@mslgroup.com 
                                                  --------------------------------- 
 
Consilium Strategic Communications (UK)    Tel:                 +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart / Sukaina          mailto:summit@consilium-comms.com 
 Virji                                             summit@consilium-comms.com 
                                                  --------------------------------- 
Lindsey Neville 
 
 
   -END-

(END) Dow Jones Newswires

November 06, 2019 07:00 ET (12:00 GMT)

Summit Therapeutics (LSE:SUMM)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025